Immunotherapy extends life for advanced head, neck cancer patients

A new immunotherapy treatment has shown promise in significantly extending the lives of patients with advanced head and neck cancer, marking the first major advancement in two decades. Clinical trials revealed that administering immunotherapy before surgery doubled the average time patients remained cancer-free, from 2.5 to five years. The treatment trains the body to fight cancer cells. The study, involving hundreds of patients across multiple countries, found a 10% reduction in cancer recurrence after three years. The findings are being presented at the American Society of Clinical Oncology meeting.